NSE · MEDICAPQ
Medi-Caps Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-1 Cr — a -590% net margin, versus -14.7% the period before.
Shareholding
As of 2026-06-30
- Promoter51.44%
- Public48.54%
- DII0.02%
10,209 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.81× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Construction · ranked #228 of 370 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| DLF Limited | ₹1,62,343 Cr | 37.74 | 3.57 | 9.71% | 65.79% |
| Lodha Developers Limited | ₹1,16,263 Cr | 28.18 | 5.13 | 14.72% | 22.69% |
| The Phoenix Mills Ltd. | ₹67,601 Cr | 51.92 | 6.15 | 11.14% | 28.16% |
| Prestige Estates Projects Ltd. | ₹66,488 Cr | 58.38 | 4.09 | 7.35% | 8.73% |
| Oberoi Realty Limited | ₹65,158 Cr | 24.61 | 3.62 | 13.99% | 41.59% |
| Godrej Properties Ltd. | ₹56,390 Cr | 34.85 | 2.94 | 9.66% | 30.76% |
| Knowledge Realty Trust | ₹50,126 Cr | 80.17 | 1.15 | 0.87% | 14.62% |
| Rail Vikas Nigam Limited | ₹42,868 Cr | 47.7 | 4.36 | 8.91% | 4.32% |
| Embassy Office Parks REIT | ₹40,674 Cr | 165.68 | 0 | 1.37% | 7.95% |
| Bagmane Prime Office REIT | ₹36,652 Cr | 41.59 | 1.03 | 0% | 29.35% |
| Medi-Caps Ltd.(this company) | ₹44 Cr | 11.25 | 0.39 | -2.72% | -14.31% |
AI analysis
AI-generated · google/gemini-2.5-flashMedi-Caps Ltd., operating in the Realty sector, has a market capitalization of Rs 32 Cr. The company's PE ratio stands at 10.76 and its book value is Rs 89.5. It reported a negative profit margin of -24.52%. The share price has ranged between Rs 21 and Rs 46.99 over the last 52 weeks.
Positives
- +The company has a low debt-to-equity ratio of 0.
- +Promoter holding is above 50% at 51.4425% as of June 30, 2026.
- +There are no pledged promoter shares, with promoter pledge at 0%.
Negatives
- −The company reported negative return on equity (ROE) of -272.15%.
- −Return on capital employed (ROCE) is negative at -2.6972%.
- −The profit margin is negative at -24.52%.
- −Earnings per share (EPS) for March 2025 was negative at -Rs 0.46.
- −The number of shareholders increased from 4310 in September 2016 to 10209 in June 2026, which may indicate increased retail interest without necessarily reflecting fundamental strength.
Financial Performance
Medi-Caps Ltd. reported a revenue of Rs 3.45 Cr for March 2026, with a net profit of Rs 3.04 Cr. In the December 2025 quarter, revenue was Rs 4.3 Cr, resulting in a net profit of -Rs 0.77 Cr. The company's annual revenue for March 2025 was Rs 28.2066 Cr, with a net profit of -Rs 0.571 Cr. More recent quarterly results show a revenue of Rs 0.53 Cr and a net profit of -Rs 0.31 Cr for March 2026.
Profitability & Returns
The company reported a return on equity (ROE) of -272.15% and a return on capital employed (ROCE) of -2.6972%. The overall profit margin is -24.52%. Earnings per share (EPS) for March 2025 was -Rs 0.46. For the three months ending March 2026, the company reported an EPS of 0. Similarly, EPS was 0 in June 2025, September 2025, and December 2025.
Balance Sheet
Medi-Caps Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 89.5. The company's financial position reflects a market capitalization of Rs 32 Cr against these metrics.
Ownership & Pledges
There are no pledged promoter shares, with promoter pledge at 0%.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.